Impulsor

Milnacipran Pierre Fabre Médicament/Impulsor is a medicine that contains the active substance milnacipran. It was to be available as capsules.

Milnacipran Pierre Fabre Médicament/Impulsor was expected to be used to treat adults with fibromyalgia, a disease causing long-lasting, widespread pain and painful responses to touch. Fibromyalgia can also cause other symptoms such as tenderness, stiffness, tiredness, anxiety and changes in how the patient sleeps, feels and thinks. The cause of fibromyalgia is not known.

The active substance in Milnacipran Pierre Fabre Médicament/Impulsor, milnacipran, is a ‘serotonin-noradrenaline re-uptake inhibitor’. It was expected to work by preventing the neurotransmitters 5-hydroxytryptamine (also called serotonin) and noradrenaline from being taken back up into nerve cells in the brain and spinal cord. Neurotransmitters are chemicals that allow nerve cells to communicate with one another. By blocking their re-uptake, milnacipran was expected to increase the level of communication between these nerve cells. Since these neurotransmitters are involved in reducing the sensation of pain, it was expected that blocking their re-uptake into nerve cells would improve the symptoms of fibromyalgia.

The effects of Milnacipran Pierre Fabre Médicament/Impulsor were first tested in experimental models before being studied in humans. In three main studies, 2,960 adult patients with fibromyalgia were given either Milnacipran Pierre Fabre Médicament/Impulsor or placebo (a dummy treatment) for around four to seven months. The main measures of effectiveness were based on the patients perceived improvement in symptoms, particularly pain levels and their overall wellbeing.

The CHMP was of the opinion that the effect of the medicine was marginal. There was also a lack of data on the long-term effects in a European population. Therefore, at that point in time, the CHMP was of the opinion that the benefits of Milnacipran Pierre Fabre Médicament/Impulsor in the treatment of fibromyalgia did not outweigh its risks. Hence, the CHMP recommended that Milnacipran Pierre Fabre Médicament/Impulsor be refused marketing authorisation. The CHMP refusal was confirmed after re-examination.

The company informed the CHMP that there are currently no ongoing clinical trials with Milnacipran Pierre Fabre Médicament/Impulsor in Europe for fibromyalgia.